Evidence map›Paper›PMID 42063078›Full record

ArticleJournal of nanobiotechnology2026

The ZIF-8 nanoplatform targeted delivery of IFI44 siRNA to suppress bladder cancer development via modulating the PI3K/AKT signaling pathway.

Chao Zhu, Mengwei Liu, Xiaohua Liu, Sifan Zhang, Yun He, Meng Chen, Haoxuan Huang, Kuai Yu, Aiping Le

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chao Zhu *Department of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Mengwei Liu *Department of Blood Transfusion, The Third Affiliated Hospital（the First Hosptial of Nanchang), Jiangxi Medical College, Nanchang University, Nanchang, China., Nanchang, 330006, Jiangxi, China.
Xiaohua Liu *NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, Nanchang, 330029, Jiangxi, People's Republic of China.
Sifan ZhangDepartment of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Yun HeDepartment of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Meng ChenDepartment of hematology, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Haoxuan HuangDepartment of Urology, The Third Affiliated Hospital（the First Hosptial of Nanchang), Jiangxi Medical College, Nanchang University, Nanchang, China, Nanchang, 330006, Jiangxi, China. hhx08120015@163.com.
Kuai YuDepartment of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China. yukuai1949@foxmail.com.
Aiping LeDepartment of Transfusion Medicine, Key Laboratory of Jiangxi Province for Transfusion Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China. ndyfy00973@ncu.edu.cn.

Funding

General Project of Jiangxi Provincial Natural Science Foundation 20232BAB206047Jiangxi Province Science and Technology Innovation Talent Project jxsq2023201037major science and technology R & D projects of Jiangxi Province 20213AAG01013Science and technology innovation base plan of Jiangxi Province-Key Laboratory of Jiangxi Province for Transfusion Medicine 2024SSY06171the National Nature Science Foundation in China 32571510the National Nature Science Foundation in China 82472225
6 · The paper itself

Abstract

Malignant progression of bladder cancer (BC) is frequently caused by its complex molecular regulation, leading to unfavorable clinical outcomes. Our research indicates that interferon-induced protein 44 (IFI44) is significantly overexpressed in BC, thereby facilitating its malignant progression. Mechanistically, BC's progression is impeded by the knockdown of IFI44, partially due to the inhibition of the PI3K/AKT signaling pathway. In addition, we constructed a Zeolitic Imidazolate Framework-8 (ZIF-8) nanoplatform, incorporating ZIF-8@siIFI44, ZIF-8@siIFI44@PEG and ZIF-8@siIFI44@PEG-RGD. Subsequent experiments demonstrated that ZIF-8@siIFI44 and ZIF-8@siIFI44@PEG possess anti-tumor property, while ZIF-8@siIFI44@PEG-RGD exhibited enhanced anti-tumor efficacy due to the inclusion of RGD targeting peptides which especially target tumors. Additionally, our study confirmed that the ZIF-8 nanoplatform enables targeted delivery of IFI44 siRNA, therefore preventing BC development partially by influencing the PI3K/AKT signaling pathway. Our findings identify IFI44 as an element that aids in the malignant development of BC, emphasizing its promise as a target for therapy.

Indexed as

NanoparticlesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Small InterferingUrinary Bladder NeoplasmsAnimalsCell Line, TumorHumansImidazolesMiceSignal TransductionImidazolesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Small InterferingBladder cancerIFI44PI3K/AKTTargeted deliveryZIF-8

Identifiers

PMID42063078
PMCPMC13285535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.